Form 4: Alnylam Pharmaceuticals Director Phillip A. Sharp Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Phillip A. Sharp exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 23, 2025, Phillip A. Sharp, a director of Alnylam Pharmaceuticals, exercised stock options to acquire 11,250 shares of common stock at a price of $131.21 per share.
- Simultaneously, Sharp sold 11,250 shares of Alnylam common stock at $275 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on August 2, 2024.
- Following these transactions, Sharp directly owns no shares and indirectly owns 266,899 shares through a trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
The filing reflects routine transactions by a company insider under a pre-arranged trading plan, which is a common practice to avoid accusations of insider trading. It doesn't necessarily indicate a change in the director's confidence in the company.
Comparison to Industry Standards
- Rule 10b5-1 trading plans are a standard practice among corporate insiders at companies like Alnylam and other pharmaceutical firms such as Moderna and BioNTech to manage their stock holdings and avoid potential insider trading accusations.
- The use of such plans allows insiders to sell shares at predetermined times and prices, regardless of any material non-public information they may possess.
- The size and frequency of these transactions are generally in line with industry norms for executive compensation and diversification strategies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/01/2016 | Stock option was fully vested and exercisable |
| 08/02/2024 | Rule 10b5-1(c) trading plan adopted by the reporting person |
| 01/23/2025 | Director exercised stock options and sold shares |
| 01/24/2025 | Date of signature for the Form 4 filing |
| 06/01/2025 | Expiration date of the stock options exercised |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.